Lastly, whether the different treatments contribute to the atrophy subtypes and whether disease-subtype-tailored treatments are efficient to delay brain and spinal cord atrophy and disease progression in similar atrophy subtypes of AQP4 + NMOSD and MS need further investigation in future clinical trials with standardized treatments. This evidence concerns the gene AQP4 and Atrophy.